{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:32:21Z","timestamp":1773757941030,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1997,3,1]],"date-time":"1997-03-01T00:00:00Z","timestamp":857174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1997,3,1]],"date-time":"1997-03-01T00:00:00Z","timestamp":857174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[1997,3]]},"DOI":"10.1016\/s0272-5231(05)70357-9","type":"journal-article","created":{"date-parts":[[2005,6,28]],"date-time":"2005-06-28T12:27:57Z","timestamp":1119961677000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["USING THERAPEUTIC DRUG MONITORING TO DOSE THE ANTIMYCOBACTERIAL DRUGS"],"prefix":"10.1016","volume":"18","author":[{"given":"Charles A.","family":"Peloquin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0272-5231(05)70357-9_bib1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJM199212173272514","article-title":"Malabsorption of antituberculosis medications by a patient with AIDS","volume":"327","author":"Berning","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/S0272-5231(05)70357-9_bib2","first-page":"773","article-title":"Isoniazid prophylaxis in Alaskan boarding schools: A comparison of two doses","volume":"100","author":"Comstock","year":"1969","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S0272-5231(05)70357-9_bib3","first-page":"177","article-title":"Ethambutol in the initial treatment of pulmonary tuberculosis","volume":"107","author":"Doster","year":"1973","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S0272-5231(05)70357-9_bib4","series-title":"Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring","first-page":"1.1","article-title":"General principles of applied pharmacokinetics. In:","author":"Evans","year":"1992"},{"key":"10.1016\/S0272-5231(05)70357-9_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2165\/00003495-198223010-00003","article-title":"Adverse effects of antituberculosis drugs","volume":"23","author":"Girling","year":"1982","journal-title":"Drugs"},{"key":"10.1016\/S0272-5231(05)70357-9_bib6","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/infdis\/168.6.1559","article-title":"Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease","volume":"168","author":"Gordon","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1016\/S0272-5231(05)70357-9_bib7","series-title":"Drug Susceptibility in the Chemotherapy of Mycobacterial Infections","first-page":"13","article-title":"Introduction: Drug susceptibility tests and the clinical outcome of chemotherapy","author":"Heifets","year":"1991"},{"key":"10.1016\/S0272-5231(05)70357-9_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0020-7101(94)90091-4","article-title":"Adaptive control of drug dosage regimens: Basic foundations, relevant issues, and clinical examples","volume":"36","author":"Jelliffe","year":"1994","journal-title":"Int J Biomed Comput"},{"key":"10.1016\/S0272-5231(05)70357-9_bib9","first-page":"1013","article-title":"Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin","volume":"107","author":"Jenne","year":"1973","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S0272-5231(05)70357-9_bib10","series-title":"Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring","first-page":"2.1","article-title":"Guidelines for the collection and analysis of pharmacokinetic data","author":"Jusko","year":"1992"},{"key":"10.1016\/S0272-5231(05)70357-9_bib11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003088-198814020-00002","article-title":"Pulse dosing versus continuous infusion of antibiotics","volume":"14","author":"LeBel","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/S0272-5231(05)70357-9_bib12","first-page":"879","article-title":"US Public Health Service cooperative trial of three rifampin\u2013isoniazid regimens in treatment of pulmonary tuberculosis","volume":"119","author":"Long","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/S0272-5231(05)70357-9_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJM199502023320518","article-title":"Drug malabsorption and resistant tuberculosis in HIV-infected patients [letter]","volume":"332","author":"Patel","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/S0272-5231(05)70357-9_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0272-2712(18)30263-4","article-title":"Therapeutic drug monitoring of the antimycobacterial drugs","volume":"16","author":"Peloquin","year":"1996","journal-title":"Clin Lab Med"},{"key":"10.1016\/S0272-5231(05)70357-9_bib15","first-page":"31","article-title":"Therapeutic drug monitoring: Principles and applications in mycobacterial infections","volume":"22","author":"Peloquin","year":"1992","journal-title":"Drug Therapy"},{"key":"10.1016\/S0272-5231(05)70357-9_bib16","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0025-7125(16)30191-2","article-title":"Pharmacology of the antimycobacterial drugs","volume":"77","author":"Peloquin","year":"1993","journal-title":"Med Clin North Am"},{"key":"10.1016\/S0272-5231(05)70357-9_bib17","unstructured":"Peloquin CA: Antimicrobial therapy. In Bittar EE (ed): Principles of Medical Biology. Jai Press Inc., in press"},{"key":"10.1016\/S0272-5231(05)70357-9_bib18","series-title":"Drug Susceptibility in the Chemotherapy of Mycobacterial Infections","first-page":"59","article-title":"Antituberculosis drugs: Pharmacokinetics","author":"Peloquin","year":"1991"},{"key":"10.1016\/S0272-5231(05)70357-9_bib19","unstructured":"Peloquin CA, Iseman MD: Antimycobacterial agents. In Root RK (ed): Clinical Infectious Diseases: A Practical Approach, in press"},{"key":"10.1016\/S0272-5231(05)70357-9_bib20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1056\/NEJM199310073291513","article-title":"Malabsorption of antimycobacterial medications","volume":"329","author":"Peloquin","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/S0272-5231(05)70357-9_bib21","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/106002809603000901","article-title":"Low anti-tuberculosis drug concentrations in patients with AIDS","volume":"30","author":"Peloquin","year":"1996","journal-title":"Ann Pharmacother"},{"key":"10.1016\/S0272-5231(05)70357-9_bib22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/sj.clpt.1996.66","article-title":"Reduced oral absorption of tuberculosis drugs in HIV infection [abstract PI-51]","volume":"59","author":"Sahai","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S0272-5231(05)70357-9_bib23","first-page":"A527","article-title":"Serum drug levels in tuberculosis patients [Abstract]","volume":"149","author":"Turner","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/S0272-5231(05)70357-9_bib24","first-page":"11","article-title":"Mode of action of antituberculous drugs (Part I)","volume":"3","author":"Verbist","year":"1974","journal-title":"Medicon Int"},{"key":"10.1016\/S0272-5231(05)70357-9_bib25","first-page":"3","article-title":"Mode of action of antituberculous drugs (Part II)","volume":"3","author":"Verbist","year":"1974","journal-title":"Medicon Int"},{"key":"10.1016\/S0272-5231(05)70357-9_bib26","series-title":"The Biology of Mycobacteria, vol 1\u2014Physiology, Identification, and Classification","first-page":"353","article-title":"Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria","author":"Winder","year":"1982"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523105703579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523105703579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:37:44Z","timestamp":1759451864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523105703579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,3]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,3]]}},"alternative-id":["S0272523105703579"],"URL":"https:\/\/doi.org\/10.1016\/s0272-5231(05)70357-9","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[1997,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"USING THERAPEUTIC DRUG MONITORING TO DOSE THE ANTIMYCOBACTERIAL DRUGS","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0272-5231(05)70357-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1997 W. B. Saunders Company. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}